Nucleic acid delivery for therapeutic applications

A Gupta, JL Andresen, RS Manan, R Langer - Advanced Drug Delivery …, 2021 - Elsevier
Recent medical advances have exploited the ability to address a given disease at the
underlying level of transcription and translation. These treatment paradigms utilize nucleic …

Current advances in RNA therapeutics for human diseases

H Zogg, R Singh, S Ro - International journal of molecular sciences, 2022 - mdpi.com
Following the discovery of nucleic acids by Friedrich Miescher in 1868, DNA and RNA were
recognized as the genetic code containing the necessary information for proper cell …

Non-coding RNAs in human health and disease: potential function as biomarkers and therapeutic targets

T Loganathan, GP Doss C - Functional & integrative genomics, 2023 - Springer
Human diseases have been a critical threat from the beginning of human history. Knowing
the origin, course of action and treatment of any disease state is essential. A microscopic …

The “cyclopropyl fragment” is a versatile player that frequently appears in preclinical/clinical drug molecules

TT Talele - Journal of medicinal chemistry, 2016 - ACS Publications
Recently, there has been an increasing use of the cyclopropyl ring in drug development to
transition drug candidates from the preclinical to clinical stage. Important features of the …

Polo-like kinase 1 (PLK1) signaling in cancer and beyond

S Iliaki, R Beyaert, IS Afonina - Biochemical pharmacology, 2021 - Elsevier
PLK1 is an evolutionary conserved Ser/Thr kinase that is best known for its role in cell cycle
regulation and is expressed predominantly during the G2/S and M phase of the cell cycle …

[HTML][HTML] PLK1, a potential target for cancer therapy

Z Liu, Q Sun, X Wang - Translational oncology, 2017 - Elsevier
Abstract Polo-like kinase 1 (PLK1) plays an important role in the initiation, maintenance, and
completion of mitosis. Dysfunction of PLK1 may promote cancerous transformation and drive …

Vimentin intermediate filaments as potential target for cancer treatment

K Strouhalova, M Přechová, A Gandalovičová… - Cancers, 2020 - mdpi.com
Intermediate filaments constitute the third component of the cellular skeleton. Unlike actin
and microtubule cytoskeletons, the intermediate filaments are composed of a wide variety of …

Plk1 inhibitors in cancer therapy: from laboratory to clinics

REA Gutteridge, MA Ndiaye, X Liu, N Ahmad - Molecular cancer therapeutics, 2016 - AACR
Abstract Polo-like kinase 1 (Plk1) overexpression has been shown to occur in a wide range
of tumors, prompting research and development of Plk1 inhibitors as a means of cancer …

Present and future perspective on PLK1 inhibition in cancer treatment

M Chiappa, S Petrella, G Damia, M Broggini… - Frontiers in …, 2022 - frontiersin.org
Polo-like kinase 1 (PLK1) is the principle member of the well conserved serine/threonine
kinase family. PLK1 has a key role in the progression of mitosis and recent evidence …

A PLK1 kinase inhibitor enhances the chemosensitivity of cisplatin by inducing pyroptosis in oesophageal squamous cell carcinoma

M Wu, Y Wang, D Yang, Y Gong, F Rao, R Liu… - …, 2019 - thelancet.com
Background Targeting PLK1 has recently been proven as a viable therapeutic strategy
against oesophageal squamous cell carcinom (ESCC). Therefore, this study aimed to …